-+ 0.00%
-+ 0.00%
-+ 0.00%
Hanyu Pharmaceutical (300199.SZ): HY3003 injection approved for drug clinical trials
Share
Listen to the news

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received the “Pharmaceutical Clinical Trial Approval Notice” for HY3003 injection approved and issued by the State Drug Administration. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The project uses a multi-dosage parallel development strategy. The development directions include HY3003 injections (weekly formulations), HY3003 extended-release injections (monthly formulations), and HY3003 tablets (once-daily oral formulation). The HY3003 injection approved for clinical trials is administered subcutaneously once a week and is intended for adult weight management indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending